Stay updated with breaking news from Program Highlights Milestones. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:
18.05.2023 - Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track ...